Challenges and opportunities in cancer drug resistance
RA Ward, S Fawell, N Floc'h, V Flemington… - Chemical …, 2020 - ACS Publications
There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …
However, even for the most successful and impactful cancer drugs which have been …
1, 2, 3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview
K Bozorov, J Zhao, HA Aisa - Bioorganic & medicinal chemistry, 2019 - Elsevier
Abstract The 1, 2, 3-triazole ring is a major pharmacophore system among nitrogen-
containing heterocycles. These five-membered heterocyclic motifs with three nitrogen …
containing heterocycles. These five-membered heterocyclic motifs with three nitrogen …
The management of metastatic GIST: current standard and investigational therapeutics
CM Kelly, L Gutierrez Sainz, P Chi - Journal of Hematology & Oncology, 2021 - Springer
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the
gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or …
gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or …
An analysis of successful hit-to-clinical candidate pairs
DG Brown - Journal of medicinal chemistry, 2023 - ACS Publications
An analysis of 156 published clinical candidates from the Journal of Medicinal Chemistry
between 2018 and 2021 was conducted to identify lead generation strategies most …
between 2018 and 2021 was conducted to identify lead generation strategies most …
Targeting gatekeeper mutations for kinase drug discovery
Y Zhou, S Xiang, F Yang, X Lu - Journal of medicinal chemistry, 2022 - ACS Publications
Clinically acquired resistance is a major challenge in cancer therapies with small-molecule
kinase inhibitors (SMKIs). Gatekeeper mutations in the ATP-binding pocket of kinases are …
kinase inhibitors (SMKIs). Gatekeeper mutations in the ATP-binding pocket of kinases are …
Small molecule inhibitors targeting the cancers
Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies
M Moradi, A Mousavi, Z Emamgholipour… - European Journal of …, 2023 - Elsevier
Angiogenesis, the formation of new blood vessels from the existing vasculature, is pivotal in
the migration, growth, and differentiation of endothelial cells in normal physiological …
the migration, growth, and differentiation of endothelial cells in normal physiological …
[HTML][HTML] A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors
Receptor tyrosine kinases play an important role in many cellular processes, and their
dysregulation leads to diseases, most importantly cancer. One such receptor tyrosine kinase …
dysregulation leads to diseases, most importantly cancer. One such receptor tyrosine kinase …
Water molecules at protein–drug interfaces: computational prediction and analysis methods
The fundamental importance of water molecules at drug–protein interfaces is now widely
recognised and a significant feature in structure-based drug design. Experimental methods …
recognised and a significant feature in structure-based drug design. Experimental methods …
Novel 1, 3-thiazole analogues with potent activity against breast cancer: A design, synthesis, in vitro, and in silico study
MG Salem, DMA El-Maaty, YIM El-Deen, BH Elesawy… - Molecules, 2022 - mdpi.com
Breast cancer is the most common cancer in women, responsible for over half a million
deaths in 2020. Almost 75% of FDA-approved drugs are mainly nitrogen-and sulfur …
deaths in 2020. Almost 75% of FDA-approved drugs are mainly nitrogen-and sulfur …